Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evotec SE (EVO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.50-0.60 (-2.60%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close23.10
Open23.26
Bid18.81 x 900
Ask22.61 x 1100
Day's Range22.29 - 23.35
52 Week Range15.80 - 26.57
Volume43,779
Avg. Volume166,734
Market Cap7.882B
Beta (5Y Monthly)0.85
PE Ratio (TTM)26.61
EPS (TTM)0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EVO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evotec SE
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Business Wire

    EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

    CAMBRIDGE, Mass. & HAMBURG, Germany, November 18, 2021--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts

  • ACCESSWIRE

    Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

    The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

  • ACCESSWIRE

    Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update

    * STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH * CO-OWNED PIPELINE GAINING MOMENTUM * J.POD (R) REDMOND (US) OPERATIONAL * SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) * GUIDANCE FOR FULL-YEAR 2021 CONFIRMED * WEBCAST AND CONFERENCE CALL TODAY AT 02.

Advertisement
Advertisement